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Highlights 
 Significant differences in HPV subtypes between HIV+ and HIV- were observed 
 The density of CD8+ T cell infiltrate correlated with the severity of lesions 











 In HIV+ patients, stromal and epithelial CD8+ T cell scores increased from LSIL to SCC 
Abstract  
 
Introduction: This study aimed to analyse cervix lymphocytic populations in HIV+ and HIV- patients and 
correlate different cervical lesions with HIV viral load and presence of high-risk HPV types. 
Material and methods: A total of 132 histological specimens from 40 HIV+ and 72 HIV- patients were 
evaluated for CD4+ and CD8+ T cell distribution, presence of high-risk HPV types, peripheral blood HIV viral 
load and CD4+/CD8+ ratio.  
Results: High-grade squamous intraepithelial lesions (HSIL) and squamous cell carcinoma (SCC) from HIV+ 
patients had lower CD4+ T cell scores compared with HIV- patients. In all lesion groups, HIV+ patients 
presented higher epithelial and stromal CD8+ T cell scores. HIV viral load was more often detectable in 
patients with SCC than in those with low-grade squamous intraepithelial lesion (LSIL) (p=0.0409). HSIL HIV+ 
patients had lower circulating CD4+ T cell counts (p=0.0434) and CD4+/CD8+ ratio (p=0.0378) compared with 
LSIL HIV+ patients. High-risk HPV types other than 16 and 18/45 were more prevalent in the HIV+ group.  
Discussion: These results support an imbalance between cervical CD4+ and CD8+ T lymphocytes of HIV+ 
patients with SIL and SCC, with increased CD8+ infiltrate density with lesion severity, even in patients with 
immune system recovery under cART.  
Keywords: carcinoma, CD4+ T cell, CD8+ T cell, cervix, HIV, viral load 
Introduction 
 
Human immunodeficiency virus (HIV)-infected (HIV+) women have a higher incidence of human papilloma 
virus (HPV)-associated cervical lesions, reduced HPV infection clearance, and higher risk of progression to 
cervical invasive neoplasia.1,2 High prevalence of high-grade cervical lesions associated with high-risk HPV is 
observed even in HIV+ women on antiretroviral therapy (ART), although early ART initiation and sustained 
therapy adherence is likely to reduce the incidence and progression of squamous intraepithelial lesions.3 
Studies investigating the role of ART in cervical cancer have included different HIV regimens and patient 
monitoring coverage methodologies, what hampers data interpretation.4,5 Current WHO guidelines 
recommend viral load testing instead of CD4+ T cell count for ART response monitoring in HIV treatment and 
prevention.6  
The more aggressive cervical lesion behavior in HIV+ compared with HIV- women may be attributed to 
systemic and local immunity alterations that weaken the immune system, promoting carcinogenesis.7–9 Both 
incidence and progression rates of cervical intra-epithelial lesions in HIV+ women have been associated with 











HPV infection can interfere with local immune vigilance mechanisms, both at the induction and effector 
phases.18 The CD4+ T cell function impairment observed in HIV infection has also been reported as a 
promoter of HPV-associated cancer.19 
Few studies have characterized the different T lymphocyte populations in intra-epithelial squamous cervical 
lesions in HIV+ patients.20–22 Kobayashi et al. reported that CD8+ T cell aggregates were predominant in HIV+ 
women with high-grade squamous intraepithelial lesions (HSIL) and were associated with worse clinical 
outcome.21 
The main aim of this study was to characterize the local immune microenvironment of squamous 
intraepithelial lesions (LSIL, HSIL), and squamous cell carcinoma (SCC) regarding presence and quantification 
of cervical CD4+ (helper) and CD8+ (cytotoxic) T lymphocytes in HIV+ women and compare it with HIV-
negative (HIV-) counterparts. Secondary aims were to correlate different cervical lesions with HIV viral load, 
CD4+ T cell counts and CD4+/CD8+ ratio, and HPV type. 
 
Material and methods 
 
A total of 112 patients were included in this study, 40 of which HIV+ and 72 HIV-. Patients included in the 
HIV+ group with SIL diagnosis were under hospital surveillance and cART treatment. Of the 16 SCC cases, 10 
were also in long-term (>1 year) hospital surveillance.  The HIV- control group consisted of women recruited 
at the Gynecology clinic of Hospital Garcia de Orta. When available and/or applicable, the following data was 
retrieved from patients’ clinical records: age, HIV status, HIV infection duration, CD4+ blood count, 
CD4+/CD8+ ratio, and HPV typing.  
Written informed consent was retrieved from all patients and the study was approved by the ethics 
committee of Hospital Garcia de Orta (HGO-CGO 23/2014), Institute of Oncology Francisco Gentil de Lisboa 
(IPO-UIC/996), and Nova Medical School (NMS-03/2015/CEFCM). 
 
Viral detection  
HIV status was determined by fourth-generation serological testing (including p24 assessment) and 
subsequently confirmed by HIV viral load quantification through real-time PCR. 
HPV typing was performed using molecular biology techniques implemented in recruitment centres, 
including HPV genotyping - CLART HPV4 (Genomica), an in vitro assay for detection and genotyping of 35 
genotypes, including high, probably high and low risk; DNA high-risk HPV typing (Cobas-Roche Diagnostics), 
an automated qualitative in vitro test for detection of HPV DNA of 14 high-risk HPV types; mRNA high-risk 











messenger RNA (mRNA) from 14 high-risk HPV types in cervical specimens; and an in-house screening 
protocol developed at IPO – Lisboa, with positive samples confirmed with INNO-LIPA/Seegene HPV28. 
 
Histological specimens 
A total of 132 histological specimens were assessed in this study, 60 from 40 HIV+ patients and 72 from 72 
HIV- patients.  
Specimens were classified as LSIL, HSIL, or SCC according to morphological type (hematoxylin- and eosin-
stained slides), supported by complementary immunohistochemical evaluation (p16 antibody – Ventana, 
Roche Diagnostics), when necessary. 
Characterization of lymphocytic populations was performed by immunohistochemistry (IHC) using SP35 
(CD4+) and SP75 (CD8+) clones (Ventana, Roche Diagnostics). These antibodies were applied to 3-µm 
sections, and a double staining detection kit (Optivision DAB; UltraView Universal AP Red) was used. Antigen 
retrieval was carried out with CC1 (Roche, Ventana) for 40 min at 97oC and stains were processed in a Roche 
Ventana BenchMark ULTRA equipment.  
CD4+ and CD8+ T lymphocyte scoring of the obtained immunostaining was performed following a modified 
version of the protocol previously described by Park & Kim,23 with immune stained-positive lymphocytes 
counted in five randomly selected high-power fields at 400X magnification and counts averaged. Scores in 
the epithelium and stroma were separately considered. CD4+ and CD8+ T cells were recorded as 1−25 cells 
(score 1), 26−50 cells (score 2), or ≥51 cells (score 3). 
 
Peripheral blood evaluation 
Peripheral blood CD4+ cell absolute counts and CD4+/CD8+ cell ratios, determined by flow cytometry using a 
4-color BD FACS Calibur (BD Biosciences), were retrieved from clinical records of 24 of the 26 HIV+  patients 
with LSIL and HSIL and 7 of the 16 HIV+ patients with SCC. HIV blood viral load, evaluated by Abbott Real-
Time HIV-1 (M2000), was also retrieved from clinical records of the same patients. 
For comparison purposes, CD4+ absolute count, CD4+/CD8+ ratio, and HIV viral load data were retrieved from 
the same year as histological samples collected. 
 
Statistical analysis 
Statistical analysis was performed with Graph Pad Prism 6. Chi Square and Fisher’s exact test were used for 
categorical variables, Mann Whitney test for continuous variables when comparing two groups, and Kruskal-
Wallis test followed by Dunn’s multiple comparisons test was used whenever three or more groups were 















Characterization of the study population  
Clinicopathological characteristics of the HIV+ and HIV- patient populations according to lesion type are 
depicted in Table 1. No significant differences were found between the two groups regarding patients’ age 
(p=0.1746), with HIV+ patients having a median of 40.5 years [IQR 34.0−47.5] and HIV- patients a median of 
41.5 years [IQR 34.0−51.0]. In subgroup analysis, HIV- women with SCC were older than their HIV+ 
counterparts (p=0.0015). 
No significant differences were found in HIV infection duration between LSIL (6.9 years) and HSIL (6.4 years) 
subgroups. In the subgroup of SCC patients, this information was limited to 6 of 16 cases. Despite this 
limitation, no significant differences were found in HIV infection duration between LSIL, HSIL, and SCC (Table 
1). 
Among the 60 cervical lesion samples (diagnosed in 46 cervical punch biopsies, 13 cervical cones, and 1 
hysterectomy specimens) from 40 HIV+ patients, 21 corresponded to LSIL, 23 to HSIL, and 16 to SCC. In the 
HIV+ group, 10 out of 40 patients provided more than one specimen, obtained throughout annual follow-up 
visits (Table 2). All 16 invasive carcinoma samples belonged to 16 different HIV+ patients.  In the HIV- control 
group, among 72 specimens (15 cervical punch biopsies, 54 cervical cones, and 3 hysterectomy specimens) 
from 72 different HIV- patients analysed, 24 corresponded to LSIL, 29 to HSIL, and 19 to SCC. In the study 
group, HIV was detected in blood of 23 of the 40 patients, specifically in 6/13 HIV+ patients with 21 LSIL 
samples, 7/11 patients with 23 HSIL samples, and 10/16 SCC patients with 16 SCC samples.   
Compared with LSIL, SCC patients had a significantly higher prevalence of detectable HIV (p=0.0409).  
Regarding blood CD4+ T cell count and CD4+/CD8+ ratio, HSIL patients displayed significantly lower CD4+ 
absolute counts (p=0.0434) and CD4+/CD8+ ratio (p=0.0378) compared with LSIL patients. No further 
differences in these parameters were observed regarding SCC, but for several of these patients, data was not 
available in clinical records, potentially influencing results obtained in the comparisons (Table 1 and Figure 
1).  
 
Characterization of HPV types in histological specimens  
Assessment of high-risk HPV types in cytological specimens was simultaneously performed at the time of 
histological sampling. In the HIV+ population, high-risk HPV was identified in 80% of patients with LSIL, 95% 
of patients with HSIL, and 89% of patients with SCC, compared to 80%, 100%, and 86% of patients in the HIV- 
population, respectively (Table 3 and Figure 2). Differences observed in the distribution of HPV types 











types other than 16, 18, and 45 being more prevalent in HIV+ patients and infection with HPV16 type more 
prevalent in HIV- patients (Table 3). 
In subgroup analyses, high-risk HPV types other than 16, 18, and 45 were present in 9/21 (43%) patients with 
LSIL, 10/20 (50%) patients with HSIL, and 1/6 (17%) of patients with SCC in the HIV+ population, compared 
with 3/20 (15%), 4/16 (25%), and 0/6 (0%) patients in the HIV- population, respectively (Table 3). 
 
Characterization of CD4+ and CD8+ T cell populations in histological specimens 
CD4+- and CD8+-positive T cells were found in histological specimens both from the epithelium and stroma in 
all LSIL, HSIL, and SCC samples (Table 4, Figures 1a, b, c, d). 
In HIV+ patients, CD4+ T cells were found in the epithelial compartment of all histological lesions. They all 
had a similar score, mostly 1 (Figures 1a, b). Regarding the stromal compartment, SCC presented higher CD4+ 
T cell scores than LSIL and HSIL, and HSIL were more frequently scored higher than LSIL. All LSIL were scored 
1 or 2, SCC lesions were scored 2 or 3, and HSIL were more frequently scored 2. In the epithelial 
compartment, no significant differences were found between LSIL, HSIL, and SCC patients regarding the 
three CD4+ T cell distribution scores, while in the stromal compartment SCC patients presented higher CD4+ T 
cell scores compared with LSIL and HSIL patients (LSIL vs SCC, p=0.0002; HSIL vs SCC, p=0.0215).  
Regarding CD8+ T cells, significant differences were found in the epithelial compartment between LSIL and 
HSIL (p=0.0043). LSIL were scored 1 and 2, while both HSIL and SCC were mostly scored 2, with a few cases 
scored 1 or 3. In the stroma, lower CD8+ T cell scores were found in LSIL, which was significantly different 
from  HSIL (p=0.0218) and SCC (p=0.0295).  
In HIV- patients, most cases of CD4+ T cells in the epithelial compartment were scored 1. In stroma, CD4+ T 
cell scores gradually increased from LSIL to SCC lesions. LSIL patients were mostly scored 1 and occasionally 
2, while all HSIL and most SCC patients were scored 3. In these patients, the distribution of cervical CD4+ T 
cells according to histological subgroups was similar to the previously described in HIV+ patients, with no 
significant differences in CD4+ scores between histological subgroups in the epithelial compartment. In 
contrast, stroma scores showed a gradual increase from LSIL to SCC, with significant score differences found 
in almost all comparisons (p<0.0001 for LSIL vs HSIL and LSIL vs SCC; p=0.0560 for HSIL vs SCC).  
Regarding CD8+ T cell distribution, differences were found between HIV- and HIV+ patients. In epithelial 
compartment, CD8+ T cells showed no significant score differences between LSIL, HSIL, and SCC. All 
subgroups predominantly displayed scores of 1, despite a slightly higher prevalence of CD8+ T cells in LSIL. In 
stromal compartment, CD8+ T cell distribution in HIV- patients followed a similar pattern of CD4+ T cells in 
the same compartment, with a gradual score increase from LSIL to SCC and statistically significant 
differences between lesions (p<0.0001 for LSIL vs HSIL and LSIL vs SCC). No significant differences were 














In this study, the local immune microenvironment of intra-epithelial lesions and cervical carcinomas from 
HIV-infected women was characterized, using HIV-uninfected women as control group. 
In accordance with previous reports,24,25 this study shows that HIV- women with SCC are older than their 
HIV+ counterparts. It should be acknowledged that, in this patient series, most HIV+ women with SCC 
(10/16) were newcomers to our health care service, mainly originating from other countries, and not 
previously exposed to ART or monitored for blood CD4+ T cell count or HIV viral load. Probably for the same 
reason, SCC patients had a significantly higher prevalence of detectable HIV load compared with LSIL 
patients.  
The CD4+ immune cell depletion observed in the blood of HIV+ individuals has been associated with 
neoplasm development, namely cervical intraepithelial neoplasia in HIV+ women with CD4+ counts <200 
cells/ul.24 This was confirmed in this study, in which lower CD4+ T cell counts and CD4+/CD8+ ratios in blood 
were associated with HSIL in the cervix. 
There has been a growing awareness on the role of the immune system in recognizing and destroying 
neoplastic cells and this way preventing the growth of several neoplasms.26,27 Nonetheless, recent studies 
also show that the immune system may simultaneously contribute to tumor development by selecting 
resistant tumor clones, promoting immunosuppression and cell proliferation, and increasing metastatic 
potential.28,29 This is considered one of the hallmarks of cancer, addressed in numerous publications 
addressing.30,31  
CD8+ T cells play a major role in anti-tumor immunity, recognizing tumor-associated antigens and eliminating 
tumor cells. It has been shown that a T cell increase in tumor microenvironment is correlated with better 
prognosis in several cancers, such as breast, colorectal, lung, and melanoma.32,33 However, tumors may 
develop mechanisms to evade immune surveillance.28,29 CD4+ T cells are equally important, as they are 
necessary to promote the development of CD8+ cytotoxic T and memory T cells, helping T cells to destroy 
tumors.26,27  
The normal CD4+ and CD8+ T cell profile is characterized by a higher density of cells per mm2 in the stromal 
compared to the epithelial compartment in normal uterine cervix, but the proportion of these cell subsets is 
similar in both compartments.34 This profile is modulated by female hormonal status.35 
Cervical CD4+ and CD8+ T cell infiltrates suffer alterations along infectious and neoplastic processes. In cervix, 
the main trigger is HPV infection. The immunophenotype, density, and distribution of lymphoid infiltrates 
depend on the malignant potential of high-risk HPV-associated lesions, and lymphoid subset characteristics 










Compared to normal cervical tissue, CD4+ T cells predominate in regressing LSIL, both within the stroma and 
epithelium, with the highest CD4+/CD8+ ratio observed in persistent LSIL compared with HSIL and invasive 
carcinoma, with CD8+ largely exceeding CD4+ cells in invasive cancers.34,36 
In invasive cervical carcinoma, tissue lymphocytes are mainly of CD8+ phenotype, with reversed CD4+/CD8+ 
ratios in cervical lymphoid infiltrates. This correlates with human cervical carcinoma progression. CD4+ T cells 
and CD4+/CD8+ ratio in tumors are significantly lower in patients with lymph node metastases compared to 
patients without lymph node metastases.39 Shah et al. also reported better prognosis for cervical cancer 
patients with higher CD4+/CD8+ ratios, with a 5-year survival rate significantly higher in patients with high 
CD4+/CD8+ ratios compared with patients with low CD4+/CD8+ ratios.16,38 In the present study, this was also 
observed in the control group of HIV- patients, confirming an increased number of stromal CD8+ T cells in 
HSIL and SCC compared with LSIL.  
Study data shows that CD4+ and CD8+ T cell counts in the local cervical microenvironment differ according to 
histological lesion type, with more severe lesions showing an increase in CD8+ T cells in both HIV+ and HIV- 
patients.  
It is established that HIV-infected women have a median three-fold higher incidence of cervical lesions and 
more commonly progress to cervical invasive neoplasia compared to HIV- women.40 This has been associated 
with progressive destruction of CD4+ T cells and loss of cell-mediated immunity in the HIV+ population, 
compromising the response to HPV infection and potentially accelerating the neoplastic process.41 
In line with our results, a previous study supports the idea that an imbalance between CD4+ and CD8+ T 
lymphocytes in the cervix of HIV+ patients with SIL may contribute to increased progression to cancer.21 
In this research, significant differences in CD4+ and CD8+ T cell populations were found both in specimens 
from HIV+ and HIV- groups. In HIV+ patients, LSIL had lower CD8+ T cell scores both in the epithelium and 
stroma compared with HSIL and SCC. In HIV- patients, a gradual increase was observed in stromal CD8+ cell 
scores from LSIL to SCC. These findings support the notion that CD8+ T cell recruitment is important in anti-
tumor immune response and increased lesion severity.42–44 The higher density of CD8+ T cells in the 
epithelium and stroma of HSIL may be directly associated with an increased recruitment of cytotoxic T cells 
and the more aggressive nature of these lesions. However, presence of an enriched cytotoxic compartment 
is not associated with lesion regression and non-progression to invasive carcinoma. 
CD8+T cell scores were significantly higher in HIV+ women with HSIL (epithelial and stromal CD8+) compared 
with HIV- women with HSIL, and the same was true for SCC, with significant differences also found between 
the epithelial and stromal compartments in HIV+ and HIV- patients. Moreover, CD4+ T cell scores were 
significantly lower in the epithelium and stroma of HIV+ patients with HSIL compared with HIV- patients. 
Regarding SCC, similar CD4+ T cell scores were found in the epithelial compartment, but HIV+ patients 











Our results confirm an increased recruitment of immune CD4+ and CD8+ T cells in lesions of HIV+ compared 
with HIV- patients and suggest a more aggressive nature of lesions, reduced HPV infection clearance, and 
diminished lesion regression in HIV+ patients. 
Our study highlights the relevance of HPV types and T lymphocytes in the HIV+ patient population. The 
importance of HPV infection in carcinogenesis has been attributed to E5, E6, and E7 HPV oncoproteins and 
how they regulate the immune response in infected patients.45 In this study, HIV+ patients had different HPV 
types associated with intra-epithelial lesions and cancer progression, confirming that HIV+ populations have 
specificities and should be followed and treated with specific protocols.  
An interesting finding from this study is that CD4+ T cell depletion in the cervix mucosa seems to mirror 
circulating CD4+ T cell depletion, with lower blood CD4+ lymphocyte counts and CD4+/CD8+ ratio particularly 
evident in HSIL.  
This research also showed that, in patients under cART, evidence of a reconstituted circulating CD4+ 
compartment (of at least 200 CD4+ T cells/uL) was not enough to prevent development of pre-invasive and 
invasive squamous lesions of the cervix. These results agree with those by Das et al. reporting that, even in 
individuals under ART, progression to cancer cannot always be prevented and the ratio of CD4+/CD8+ T 
lymphocyte infiltration in cervical cancer is significantly lower than in peripheral blood, especially in 
advanced stages of disease.46 This is probably due to persistent alterations in the lymphocytic population of 
the local microenvironment. Curiously, in 2017 McBride et al. suggested that the CD4+/CD8+ ratio may be a 
better marker of disease progression, morbidity, and mortality risk in HIV patients.47 
Interestingly, Perdomo-Celis and colleagues reported that CD8+ T cells from patients on cART exhibit 
decreased degranulation capacity.48 This defect was mainly seen in effector memory cells with high CD57 
expression. Thus, although cART can achieve HIV viral suppression, CD8+ T cells from HIV+ patients under 
cART may have an alteration in their cytotoxic program commonly associated with alterations in cellular 
activation, differentiation, exhaustion, and inflammation. This may explain why cART is not completely 
effective in the prevention of cervical HSIL and cancer development, as observed in this study. 
Further studies on the function of different lymphocytes present in the cervix may better clarify this 
hypothesis and enable the development of new therapies, eventually linked to the impaired function of local 
lymphocytes, including regulatory immune cells. 
The present scenario may change, as vaccines are being developed to improve the immune response to HPV-
induced lesions and cancer. Welters et al. reported that the HPV16 E6 and E7 synthetic long peptide vaccine 
can vigorously enhance the number and activity of HPV16-specific CD4+ and CD8+ T cells.49 The expansion of 
both types of HPV16 (tumor)-specific T cells indicates the potential of this type of vaccine as immunotherapy 











Several issues still need to be addressed, as vaccination may not induce development of HPV-specific T cells 
capable of attacking the tumor. Indeed, as shown in this study, vaccine spectrum should consider other high-
risk HPV types distinct from 16 and 18, which are more prevalent in HIV+ patients with SIL than in HIV- 
patients. 
The fact that, in HIV+ patients, SILs already show prominent alterations of density and CD4+/CD8+ T cell 
ratio, even in patients with cART-reconstituted immune system, may explain the sustained aggressive 
behavior of these lesions, and bring into consideration the use of therapeutic vaccines at this stage.  
Although this study has not addressed the full immune complexity of HIV+ women’s cervix, retrieved data 
suggests the occurrence of alterations in the immune cell infiltrate of cervix microenvironment consisting in 
significantly increased CD8+ T cell populations and higher prevalence of different high-risk HPV types other 
than 16 and 18. This suggests that specific clinical follow-up protocols should be developed taking into 
account different types of high-prevalent HPV infection. Additionally, therapeutic strategies seeking to 
mirror the natural immune response and the promising diagnostic use of digital pathology software to 
prospectively explore cervical CD4+ and CD8+ T cells populations in HIV+ patients may be relevant for cancer 
prevention in these patients. 
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Table 1. Clinicopathological characteristics of HIV+ and HIV- patient populations according to lesion type. 
Population Lesion 
type 
Age (years) Known Infection 
duration (years) 
Histological 
specimen type  










B = 19 (90.5%) 
C = 2 (9.5%) 
H = 0 (0.0%) 
Detectable: 6 (28.6%) 











B = 9 (39.1%) 
C = 13 (56.5%) 
H = 1 (4.4%) 
Detectable: 7 (38.9%) 
Non-detectable: 11 (61.1%) 











B = 10 (62.5%) 
C = 6 (37.5%) 
H = 0 (0.0%) 
Detectable: 10 (66.7%) 
Non-detectable: 5 (33.3%) 









n/a B = 2 (8.3%) 
C = 22 (91.7%) 
H = 0 (0.0%) 





n/a B = 3 (10.3%) 
C = 25 (86.2%) 
H = 1 (35%) 





n/a B = 7 (36.8%)  
C = 9 (47.4%) 
H = 3 (15.8%) 
n/a n/a n/a 
B, biopsy; C, cone; H, hysterectomy; HIV, human immunodeficiency virus; HSIL, high-grade squamous intraepithelial lesion; LSIL, low-grade squamous intraepithelial 

















Biopsy Cone Hysterectomy LSIL HSIL SCC Total 
1 3   3   3 
2 1   1   1 
3 1   1   1 
4 1   1   1 
5 1   1   1 
6 1   1   1 
7 2   1 1  2 
8 1   1   1 
9 2    2  2 
10 2   1 1  2 
11 3 1  1 3  4 
12 3   2 1  3 
13 1   1   1 
14 1    1  1 











16 1   1   1 
17 1   1   1 
18 3 2  1 3  4 
19  1   1  1 
20  1   1  1 
21  1   1  1 
22 1     1 1 
23 1     1 1 
24 1     1 1 
25 1     1 1 
26  1    1 1 
27  1    1 1 
28  1    1 1 
29  1    1 1 
30 1     1 1 
31 2 1   3  3 
32 1    1  1 
33 1    1  1 











35 2 1   2 1 3 
36  1    1 1 
37 1     1 1 
38 1     1 1 
39 1     1 1 
40   1   1 1 


















Table 3. High-risk HPV types according to lesion subgroups. 
 
LSIL HSIL SCC 
HPV type HIV+ HIV- HIV+ HIV- HIV+ HIV- 
16 2 11 5 12 3 4 
18/45 0 0 0 0 0 1 
16+18/45 0 1 0 0 1 0 
16,18+45+other high-risk 
types 5 1 4 0 1 1 
Other high-risk, non 16,18+45 
types 9 3 10 4 1 0 
High-risk negative 5 4 1 0 0 0 
Number of tested specimens 21 20 20 16 6 6 
HIV, human immunodeficiency virus; HPV, human papillomavirus; HSIL, high-grade squamous intraepithelial lesion; LSIL, low-grade squamous intraepithelial lesion; 












































1 20/21 23/24 10/21 16/24 9/21 21/24 1/21 24/24 
2 1/21 1/24 11/21 8/24 12/21 3/24 12/21 0/24 
3 0/21 0/24 0/21 0/24 0/21 0/24 8/21 0/24 
HSIL 
1 23/23  23/29 6/23 0/29 1/23 18/29 0/23 1/29 
2 0/23 6/29 14/23 0/29 19/23 11/29 5/23 23/29 
3 0/23  0/29 3/23 29/29 3/23 0/29 18/23 5/29 
SCC 
1 14/16 16/19 0/16 0/19 3/16 14/19 0/16 0/19 
2 2/16 3/19 9/16 3/19 11/16 5/19 3/16 12/19 
3 0/16 0/19 7/16 16/19 2/16 0/19 13/16 7/19 
 








































































Figure 1. CD4+ (brown) and CD8+ (red) dual immunohistochemical staining in cervical lesions. 
a) Low-grade squamous cell lesion in an HIV+ patient showing few intraepithelial and stromal CD4+ cells and CD8+ cell predominance in the stroma and 
basal layer; b) HIV+ patient with glandular colonization by high-grade squamous intraepithelial lesion, with heavy intraepithelial (basal layer) and 
stromal CD4+ and CD8+ cell infiltrate with CD8+ cell predominance; c) HIV+ squamous cell carcinoma showing CD8+ cell predominance, both in the 
Group Age (years) Known Infection  
duration (years) Type of specimen  HIV/Viral load  (same year of collection) CD4 Absolute counts (cells/ ?L) (same year of collection) CD4/CD8 (same year of collection) 
HIV LSIL n=21 
38,0 
[35,0; 46,0] 7,0 [3,0; 11,0] 
B = 19 (90,5%) 
C = 2 (9,5%) 
H = 0 (0,0%) 
Detectable = 6 (28,6%) 
ND = 15 (71,4%) 469,0 [269,5; 619,0] 53,0 [42,0; 91,0] 
HIV HSIL n=23 
36,0 
[29,0; 42,0] 6,5 [2,0; 12,3] 
B = 9 (39,1%) 
C = 13 (56,5%) 
H = 1 (4,4%) 
Detectable = 7 (38,9%) 
ND = 11 (61,1%) 
NOT AVAILABLE = 5 
220,0 
[87,5; 546,5] 36,0 [20,5; 63,5] 
HIV CPC n=16 
44,5 
[43,0; 55,3] 7,5 [4,5; 13,0] 
B = 10 (62,5%) 
C = 6 (37,5%) 
H = 0 (0,0%) 
Detectable = 10 (66,7%) 
ND = 5 (33,3%) 
NOT AVAILABLE = 1 
219,0 
[109,5; 594,0] 40,0 [18,0; 61,0] 
NON HIV LSIL n=24 
37,5 
[32,3; 45,8] 
B = 2 (8,3%) 
C = 22 (91,7%) 
H = 0 (0,0%) 




B = 3 (10,3%) 
C = 25 (86,2%) 
H = 1 (3,5%) 
NON HIV CPC n=19 
65,0 
[36,0; 71,0] 
B = 7 (36,8%) 
C =  9 (47,4%) 
H = 3 (15,8%) 
(B=biopsy, C=cone, H= hysterectomy)(Year of collection) 
Group Age (years) Known Infection  
duration (years) Type of specimen  
HIV/Viral load   
(same year of collection) 
CD4 Absolute counts (cells/ ?L) 
(same year of collection) 
CD4/CD8  
(same year of collection) 





B = 19 (90,5%) 
C = 2 (9,5%) 
H = 0 (0,0%) 
Detectable = 6 (28,6%) 










B = 9 (39,1%) 
C = 13 (56,5%) 
H = 1 (4,4%) 
Detectable = 7 (38,9%) 
ND = 11 (61,1%) 










B = 10 (62,5%) 
C = 6 (37,5%) 
H = 0 (0,0%) 
Detectable = 10 (66,7%) 
ND = 5 (33,3%) 





NON HIV LSIL n=24 
37,5 
[32,3; 45,8] 
B = 2 (8,3%) 
C = 22 (91,7%) 
H = 0 (0,0%) 




B = 3 (10,3%) 
C = 25 (86,2%) 
H = 1 (3,5%) 
NON HIV CPC n=19 
65,0 
[36,0; 71,0] 
B = 7 (36,8%)  
C =  9 (47,4%) 
H = 3 (15,8%) 











epithelium and stroma; d) HIV- patient with squamous cell carcinoma with low CD8+ cell density both in the epithelium and stroma compared with the 
HIV+ patient depicted in c). 
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